Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.
Julg B., Dee L., Ananworanich J., Barouch DH., Bar K., Caskey M., Colby DJ., Dawson L., Dong KL., Dubé K., Eron J., Frater J., Gandhi RT., Geleziunas R., Goulder P., Hanna GJ., Jefferys R., Johnston R., Kuritzkes D., Li JZ., Likhitwonnawut U., van Lunzen J., Martinez-Picado J., Miller V., Montaner LJ., Nixon DF., Palm D., Pantaleo G., Peay H., Persaud D., Salzwedel J., Salzwedel K., Schacker T., Sheikh V., Søgaard OS., Spudich S., Stephenson K., Sugarman J., Taylor J., Tebas P., Tiemessen CT., Tressler R., Weiss CD., Zheng L., Robb ML., Michael NL., Mellors JW., Deeks SG., Walker BD.
Analytical antiretroviral treatment interruption (ATI) is an important feature of HIV research, seeking to achieve sustained viral suppression in the absence of antiretroviral therapy (ART) when the goal is to measure effects of novel therapeutic interventions on time to viral load rebound or altered viral setpoint. Trials with ATIs also intend to determine host, virological, and immunological markers that are predictive of sustained viral control off ART. Although ATI is increasingly incorporated into proof-of-concept trials, no consensus has been reached on strategies to maximise its utility and minimise its risks. In addition, differences in ATI trial designs hinder the ability to compare efficacy and safety of interventions across trials. Therefore, we held a meeting of stakeholders from many interest groups, including scientists, clinicians, ethicists, social scientists, regulators, people living with HIV, and advocacy groups, to discuss the main challenges concerning ATI studies and to formulate recommendations with an emphasis on strategies for risk mitigation and monitoring, ART resumption criteria, and ethical considerations. In this Review, we present the major points of discussion and consensus views achieved with the goal of informing the conduct of ATIs to maximise the knowledge gained and minimise the risk to participants in clinical HIV research.